Safety and Efficacy of Triple Combination Therapy With Dorzolamide Hydrochloride / Brimonidine Tartrate / Timolol Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension

Study Identifier
Dorzo-Brimo-Timo/2010
CT.gov Identifier
NCT01284166
EudraCT Identifier
Not available
EUCTIS ID
Not available
For general inquiries, please contact

844-663-3742 or [email protected]

Other
Sign up for trial alerts

Study Details

Medical Condition
  • Glaucoma - Other
  • Ocular Hypertension
    • Study Drug
  • dorzolamide hydrochloride 2.0%/brimonidine tartrate 0.2%/timolol 0.5% ophthalmic solution
    • Phase
    Phase 3
    Sex
    Female & Male
    Age
    18+ years
    Inclusion and Exclusion Criteria
    Inclusion Criteria:
    * Diagnosis of ocular hypertension or glaucoma in each eye * Requires IOP-lowering treatment in both eyes
    Exclusion Criteria:
    * Use of dorzolamide or carbonic anhydrase within 4 weeks * Any other active ocular disease other than ocular hypertension or glaucoma (eg, uveitis, ocular infections or severe dry eye) * Required chronic use of ocular medications other than study medication during the study (intermittent use of certain products eg, artificial tears are permitted) * Use of oral, injectable or topical ophthalmic steroids within 21 days * Any eye laser surgery within 3 months * Any intraocular surgery (eg cataract surgery) within 6 months

    Protocol Summary

    This study will investigate the safety and efficacy of Triple Combination Therapy with dorzolamide hydrochloride/brimonidine tartrate/timolol ophthalmic solution in patients with glaucoma or ocular hypertension who have elevated IOP on dorzolamide hydrochloride/timolol maleate combination therapy.

    Study Locations

    No locations found.